Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SGK1 | O00141 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443990 | 0.90 | ALDH1A1 (0.50) | HIF1AALDH1A1EGLN1STK17B | |
| SCHEMBL14826038 | 0.85 | EGLN1 (0.58) | SMN1; SMN2HIF1AALDH1A1EGLN1STK17B | |
| SCHEMBL29929320 | 0.84 | HIF1A (0.55) | HIF1AALDH1A1CTSA | |
| SCHEMBL71034 | 0.84 | HIF1A (0.55) | HIF1AALDH1A1CTSA | |
| SCHEMBL14838812 | 0.83 | EGLN1 (0.42) | MAPTSMN1; SMN2HIF1AALDH1A1CTSA | |
| SCHEMBL14815618 | 0.83 | GRIN1 (0.45) | SMN1; SMN2HIF1AALDH1A1EGLN1USP30 | |
| Hydrochloric Acid SCHEMBL28470042 | 0.82 | HIF1A (0.54) | HIF1AALDH1A1CTSA | |
| Ethylene SCHEMBL29031104 | 0.81 | HIF1A (0.53) | HIF1AALDH1A1CTSA | |
| SCHEMBL2554720 | 0.81 | HIF1A (0.56) | HIF1ACTSAEGLN1MEN1KMT2A | |
| SCHEMBL11047806 | 0.81 | HIF1A (0.53) | SMN1; SMN2HIF1ACTSAEGLN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573086-A1 | METHANOGEN INHIBITORS | Agrizeronz Limited Partnership (NZ) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998272-A | Methanogen inhibitors | 阿格里泽伦茨有限合伙公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2024039250-A1 | METHANOGEN INHIBITORS | PASTORAL GREENHOUSE GAS RESEARCH LIMITED (NZ) | 2024-02-22 | — | — | WO | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20220223795-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2021045460-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | 엘티소재주식회사 | 2021-03-11 | — | — | WO | disclosed |
| WO-2005092304-A2 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2005-10-06 | — | — | WO | disclosed |
| CN-1056840-C | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | MAPT 2349/4885SMN1; SMN2 2367/4885HIF1A 445/4885 |
| US-20220223795-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | CRY1, CYP1A1, CYP1B1 | MAPT 1857/4885SMN1; SMN2 3932/4885HIF1A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.